Latest News

VIRALEZE™ registered in Vietnam with launch this week (ASX Announcement)

Dec 1st, 2021

Starpharma today announced it has received confirmation that VIRALEZE™ antiviral nasal spray has been registered for sale in Vietnam. The product launch is scheduled to occur in Vietnam this week with product supplied under the initial supply distribution arrangements, with Australian-based Healthco Australia Pty Ltd (HealthCo), and Vietnam-based Truong Bao Land International Investment Company Limited (TBL). TBL will also utilise the local medical distribution networks in Vietnam, including Nam Thanh Trade and Medical Services Company Limited.

Read More

AGM Chairman’s address and CEO’s presentation (ASX Announcement)

Nov 30th, 2021

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.

Read More

Starpharma reports positive interim results from Phase 2 DEP cabazitaxel study in prostate cancer

Nov 27th, 2021

Starpharma's positive interim results from its ongoing phase 2 trial of DEP cabazitaxel featured in Seeking Alpha. 

Read More

Starpharma Releases Positive DEP® Phase 2 Interim Results In Prostate Cancer

Nov 27th, 2021

British Herald reports on Starpharma's announcement, regarding the positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel.

Read More

In the media

AGM Chairman’s address and CEO’s presentation (ASX Announcement)

Nov 30th, 2021

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.

Read More

Starpharma (ASX:SPL) continues VIRALEZE success in December quarter

Oct 29th, 2021

"Starpharma (SPL) has released its September quarterly report, with the quarter again highlighted by the continued success of VIRALEZE," as reported by The Market Herald. 

Read More

Starpharma signs distribution agreement for antiviral in Vietnam

Oct 26th, 2021

News of Starpharma signing an initial supply contract for VIRALEZE™ in Vietnam featured in BiotechDispatch. Read the article here

Read More

Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Oct 26th, 2021

The Market Herald features news of Starpharma's latest supply arrangement for VIRALEZE™ in Vietnam.

Read More

Shareholder Updates

Shareholder Update April 2021

Apr 28th, 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – April 2021 is now available to view online.

Read More

Shareholder Update October 2020

Oct 20th, 2020

In this issue:

>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray

>> Rapid progress in the DEP® irinotecan phase 2 & preparations underway for clinical combinations

>> DEP® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models

>> VivaGel® BV launched in Central & Eastern Europe and Nordic region

>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication

>> VivaGel® BV has now been approved in 40 countries with further submissions underway

>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray

>> DEP® docetaxel update & patient case study

>> DEP® cabazitaxel update & patient case study

>> Multiple DEP® products showcased at AACR 2020 Annual Meeting

>> New DEP® partnership signed with Chase Sun for anti-infective program

>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center

>> Starpharma creates slow release soluble DEP® remdesivir

>> DEP® partnering, including Antibody Drug Conjugates

>> DEP® lutetium; impressive efficacy in human prostate cancer model

>> Outlook, Annual Report & ESG Report & recent news 

Read More

Sign up to receive news here